SCHEMBL16627014

SCHEMBL16627014

COc1ccc2c(c1)CCN1[C@H](Cc3ccccc3)c3c(ccc(OC)c3O)C[C@@H]21

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.65
KDM4E B2RXH2 1/20 0.59
MEN1 O00255 1/20 0.59
ALDH1A1 P00352 1/20 0.59
CYP3A4 P08684 1/20 0.59
MAPT P10636 1/20 0.59
HPGD P15428 1/20 0.59
KMT2A Q03164 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
BCHE P06276 1/20 0.56
ACHE P22303 1/20 0.56
DRD1 P21728 3/20 0.47
DRD2 P14416 2/20 0.47
DRD4 P21917 1/20 0.47
DRD5 P21918 1/20 0.47
DRD3 P35462 1/20 0.47
HCRTR1 O43613 2/20 0.46
ADRA1A P35348 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16625822 0.90 KCNH2 (0.64) KCNH2KDM4EMEN1ALDH1A1CYP3A4
SCHEMBL16626854 0.87 BCHE (0.50) KCNH2KDM4EALDH1A1CYP3A4BCHE
SCHEMBL16627558 0.87 KCNH2 (0.53) KCNH2KDM4EMEN1ALDH1A1CYP3A4
SCHEMBL16627052 0.85 KCNH2 (0.57) KCNH2KDM4EMEN1ALDH1A1CYP3A4
SCHEMBL16627053 0.85 DRD1 (0.49) KCNH2KDM4EALDH1A1CYP3A4MAPT
SCHEMBL16625819 0.84 CYP3A4 (0.82) KCNH2KDM4EMEN1ALDH1A1CYP3A4
SCHEMBL16627012 0.81 DRD1 (0.48) KDM4EALDH1A1CYP3A4KMT2ABCHE
SCHEMBL29527040 0.79 KCNH2 (1.00) KCNH2KDM4EMEN1ALDH1A1CYP3A4
SCHEMBL16625808 0.78 KCNH2 (0.48) KCNH2KDM4EMEN1ALDH1A1CYP3A4
SCHEMBL16625844 0.77 KCNH2 (0.52) KCNH2KDM4EMEN1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181237-B2 Substituted berbines and their synthesis MALLINCKRODT LLC (US) 2015-11-10 US disclosed
WO-2015051106-A1 SUBSTITUTED BERBINES AND THEIR SYNTHESIS MALLINCKRODT LLC (US) 2015-04-09 WO disclosed
US-20150099772-A1 SUBSTITUTED BERBINES AND THEIR SYNTHESIS SUCAMPO PHARMA AMERICAS LLC 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099772-A1 SUBSTITUTED BERBINES AND THEIR SYNTHESIS TYMS, NME2, TYMP KCNH2 2170/4885KDM4E 171/4885MEN1 945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.